DUBLIN, October 17, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/7jx6nq/china) has announced the addition of the "China Interventional Cardiovascular Device Industry Report,2014-2017" report to their offering.
The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion.
At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.
Interventional cardiovascular devices in China include cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices, etc., among which cardiovascular stent is predominant.
Cardiovascular stent: In 2013, the Chinese cardiovascular stent market equaled RMB11.2 billion, 78.8% of which was occupied by domestic drug-eluting stents. That same year, 686,000 units of cardiovascular stent were consumed in China, up 11.7% year on year, and drug-eluting stents accounted for 99.5%, indicating that the drug-eluting stent is gradually becoming an important device for interventional cardiovascular therapy.
In addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop biodegradable stents, which are expected to be available on the market in 2017. Thanks to its excellent performance, biodegradable stents are likely to replace drug-eluting stents gradually in the future, thus becoming the main variety in domestic coronary stent market.
Balloon catheter: In 2013, China's demand for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which were PTCA balloon catheters for dilatation. With rapid development of local PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW Medical, domestic PTCA balloon catheters increased its market share from 20% in 2009 to 40% in 2013.
Affected by the implementation of Regulations on the Centralized Procurement of High-value Medical Consumables, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017.
Key Topics Covered:
1. Overview of Interventional Cardiovascular Device Industry
2. Status Quo of China Interventional Cardiovascular Device Industry
3. Development Environment of China Interventional Cardiovascular Device Industry
4. Market Segments of China Interventional Cardiovascular Device Industry
5. Foreign Companies in China
6. Major Domestic Companies
7 Forecast and Outlook
- Abbott Laboratories
- AmsinoMed Medical Device
- B. Braun
- Boston Scientific
- Dalian Yinyi
- Demax Medical
- JW Medical
- Johnson & Johnson
- Lepu Medical
- Lifetech Scientific
- Neich Medical (Shenzhen)
- SCW Medicath
- Sino Medical
- Starway Medical
For more information visit http://www.researchandmarkets.com/research/7jx6nq/china
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets